Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 138.41 Delayed Data As of Jan 20 |  -0.31 / -0.22%Today’s Change | 125.08 Today|||52-Week Range 212.00 | -18.38% Year-to-Date |
Latest ALNY News | Press Releases
No recent news for Alnylam Pharmaceuticals Inc.
Today’s Trading
| Previous close | 138.62 |
| Today’s open | 146.16 |
| Day’s range | 137.90 - 146.44 |
| Volume | 576,251 |
| Average volume (3 months) | 717,985 |
| Market cap | $17.7B |
Data as of 4:00pm ET, 01/20/2022
Growth & Valuation
| Earnings growth (last year) | +7.96% |
| Earnings growth (this year) | +13.19% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +124.28% |
| P/E ratio | NM |
| Price/Sales | 30.32 |
| Price/Book | 16.99 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| INCYIncyte Corp | -0.02 | -0.03% |
| CTLTCatalent Inc | +0.05 | +0.05% |
| VTRSViatris Inc | -0.08 | -0.54% |
| HZNPHorizon Therapeutics... | -1.47 | -1.67% |
Data as of 4:00pm ET, 01/20/2022
Financials
| Next reporting date | February 10, 2022 |
| EPS forecast (this quarter) | -$1.56 |
| Annual revenue (last year) | $492.9M |
| Annual profit (last year) | -$858.3M |
| Net profit margin | -174.15% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
